ClinicalTrials.gg
Not yet recruitingNCT07946276Updated Nov 18, 2026

AI Assistance for Clinicians Identifying Causes of Chest Pain From ECG Images

An interventional study of ZERO-generated report assistance in Chest Pain, Unstable Angina (UA) and ST Elevation Myocardial Infarction (STEMI), sponsored by Peking University Health Science Center. Not yet recruiting. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionAngina, UnstableRegistry: Chest PainReclassifiedWhy we changed it
Registry
Chest Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Angina, Unstable
Why
  1. The study's listed conditions name Angina, Unstable, a narrower term within Chest Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Peking University Health Science Center · Not applicable, Interventional, and Diagnostic

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 110 Years
Sex
All
01

Study summary

This study will assess whether reports generated by ZERO, a mobile system for interpreting electrocardiogram (ECG) images, improve clinicians' ability to identify causes of chest pain compared with interpretation without AI assistance.

A total of 120 licensed cardiology clinicians will be randomly assigned in a 1:1 ratio to ZERO-assisted or unassisted interpretation. Each clinician will assess 30 ECG cases during a single session lasting up to 60 minutes. The cases will include five examples from each of six diagnostic categories: unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, aortic dissection, pulmonary embolism, and other diagnoses. No case or patient will be repeated within or across clinicians.

For each case, clinicians will first review the ECG and submit an initial diagnosis that cannot subsequently be changed. Clinicians in the ZERO-assisted group will then view a fixed report generated before clinician randomization. Clinicians in the unassisted group will review the ECG again without an AI report. All clinicians will then submit a final diagnosis.

Diagnostic performance will be assessed against clinical reference diagnoses established before the interpretation task and withheld from participating clinicians. The study will use ECG cases from completed clinical encounters and will not affect patient care. The hypothesis is that ZERO-assisted clinicians will achieve higher final diagnostic accuracy than unassisted clinicians.

02

Conditions studied

  • Chest Pain
  • Unstable Angina (UA)
  • ST Elevation Myocardial Infarction (STEMI)
  • Non-ST Elevation Myocardial Infarction (nSTEMI)
  • Aortic Dissection
  • Pulmonary Embolism (Diagnosis)

Keywords

  • Artificial Intelligence
  • Electrocardiography
  • Clinical Decision Support
  • ECG Image Interpretation
  • Cardiologists
03

In context

Angina, Unstable Reclassified

331 studies on the registry are indexed under Angina, Unstable; 45 are open to participants now.

This study's planned enrollment of 120 is below the median of 212 across 201 interventional studies indexed under Angina, Unstable.

Browse Angina, Unstable studies →

Lead sponsor

Peking University Health Science Center is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Angina, Unstable, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Chest Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Licensed cardiology clinicians who routinely participate in the diagnosis or management of chest pain or cardiovascular disease and interpret (ECGs).
  • Able to read Chinese-language reports and use the study platform.
  • Willing to provide electronic and sign a confidentiality statement.
  • Willing to complete all 30 assigned ECG interpretation tasks within the specified study period.

Exclusion criteria

Exclusion Criteria:

  • Access to the reference diagnoses of the study cases, or involvement in screening, selecting, or adjudicating these cases.
  • Prior knowledge of the answers to the study cases through participation in model development or previous experiments.
  • Duplicate enrollment.
  • Inability to complete training in the use of the study platform.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • No intervention
    No AI Assistance

    Clinicians will interpret 30 unique ECG cases, with five cases from each diagnostic category, during a single session lasting up to 60 minutes. For each case, clinicians will review the ECG image and submit an initial first-choice diagnosis, which will then be locked. They will subsequently review the same ECG image again without an AI report and submit a final first-choice diagnosis, which will also be locked.

  • Experimental
    ZERO Assistance

    Clinicians will first review each assigned ECG image and submit and lock an initial first-choice diagnosis. They will then view the fixed ZERO-generated report and submit and lock a final first-choice diagnosis. The report will include risk alerts for STEMI, aortic dissection, and pulmonary embolism, ranked diagnostic candidates, supporting explanations and available sources, and suggestions for further evaluation. If the report is unavailable or invalid, the failure will be recorded and the clinician may still submit a final diagnosis. Each clinician will complete 30 unique cases, with five cases per diagnostic category.

    Other: ZERO-generated report assistance

Interventions

  • OtherZERO-generated report assistance

    ZERO is a mobile system that processes de-identified ECG images and generates structured diagnostic reports. It integrates image preprocessing, a dedicated prediction model, risk stratification, knowledge retrieval, and report generation using GLM-4.6. Reports will be generated and stored before clinician randomization using a prespecified, frozen model, prompts, and retrieval configuration. During the interpretation task, the corresponding report will be displayed only after the clinician has submitted and locked the initial diagnosis. No additional patient information or clinician responses will be supplied to the system, and reports will not be modified during the task. No online adaptation will occur during the study.

    Also known as: ZERO

06

What researchers measure

Primary outcomes

  1. Finalfirst-choice diagnostic accuracy

    For each clinician, final first-choice diagnostic accuracy will be calculated as the number of cases in which the final first-choice diagnosis matches the prespecified clinical reference diagnosis, divided by 30 and multiplied by 100%. Each clinician will assess five cases from each of six diagnostic categories. The outcome will be summarized as the mean clinician-level accuracy in each randomized group. Only clinicians with both an initial and a final diagnosis recorded for all 30 cases will be included in the diagnostic outcome analysis. The primary comparison will be between the ZERO-assisted and unassisted groups.

    Time frame: 60 Minutes

Secondary outcomes

  1. Final Missed-Diagnosis Percentage for ST-Segment Elevation Myocardial Infarction

    Among clinicians with complete initial and final diagnoses for all 30 cases, the percentage of cases with a reference diagnosis of ST-segment elevation myocardial infarction for which the final first-choice diagnosis is not ST-segment elevation myocardial infarction. Each clinician's percentage will be calculated as the number of such cases divided by five and multiplied by 100%. The outcome will be summarized as the mean clinician-level percentage in each randomized group. Lower values indicate fewer missed diagnoses in the ECG interpretation task.

    Time frame: 60 Minutes

  2. Final Missed-Diagnosis Percentage for Aortic Dissection

    Among clinicians with complete initial and final diagnoses for all 30 cases, the percentage of cases with a reference diagnosis of aortic dissection for which the final first-choice diagnosis is not aortic dissection. Each clinician's percentage will be calculated as the number of such cases divided by five and multiplied by 100%. The outcome will be summarized as the mean clinician-level percentage in each randomized group. Lower values indicate fewer missed diagnoses in the ECG interpretation task.

    Time frame: 60 Minutes

  3. Final Missed-Diagnosis Percentage for Pulmonary Embolism

    Among clinicians with complete initial and final diagnoses for all 30 cases, the percentage of cases with a reference diagnosis of pulmonary embolism for which the final first-choice diagnosis is not pulmonary embolism. Each clinician's percentage will be calculated as the number of such cases divided by five and multiplied by 100%. The outcome will be summarized as the mean clinician-level percentage in each randomized group. Lower values indicate fewer missed diagnoses in the ECG interpretation task.

    Time frame: 60 Minutes

  4. Proportion of Cases Revised From an Incorrect to a Correct Diagnosis

    For each clinician, the proportion will be calculated as the number of cases in which the initial first-choice diagnosis does not match the reference diagnosis but the final first-choice diagnosis does match it, divided by 30 and multiplied by 100%. The outcome will be summarized as the mean clinician-level proportion in each randomized group. The analysis will include only clinicians with complete initial and final diagnoses for all 30 assigned cases. Higher values indicate that more cases were corrected during the second assessment.

    Time frame: 60 Minutes

  5. Proportion of Cases Revised From a Correct to an Incorrect Diagnosis

    For each clinician, the proportion will be calculated as the number of cases in which the initial first-choice diagnosis matches the reference diagnosis but the final first-choice diagnosis does not match it, divided by 30 and multiplied by 100%. The outcome will be summarized as the mean clinician-level proportion in each randomized group. The analysis will include only clinicians with complete initial and final diagnoses for all 30 assigned cases. Lower values indicate that fewer initially correct diagnoses became incorrect during the second assessment.

    Time frame: 60 Minutes

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2026, 0 months later.

Of 42 non-industry interventional studies with no phase under Angina, Unstable, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 0 months is below that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 19, 2026
Primary completionEst.
Dec 11, 2026
CompletionEst.
Dec 18, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946276
Lead sponsor
Peking University Health Science Center
Responsible party
Shenda Hong (Assistant Professor, Peking University Health Science Center) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 19, 2026 (estimated)
Primary completion
Dec 11, 2026 (estimated)
Completion
Dec 18, 2026 (estimated)
Last update
Nov 18, 2026

Study contacts

Shenda Hong, Ph.D
Contact
hongshenda@pku.edu.cn
+8615201360928

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion